News Center

• Apr. 21

  2023

  VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL

• Apr. 01

  2023

  VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL

• Mar. 22

  2023

  VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA

• Mar. 13

  2023

  NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION

• Mar. 11

  2023

  FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (多恩達®) (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASO

• Mar. 02

  2023

  NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA